摘要
目的探讨碳酸锂联合131I治疗Graves病(GD)的疗效。方法用碳酸锂联合131I治疗GD患者5638例,对其临床资料进行回顾性分析。结果碳酸锂联合131I治疗GD,一次治疗后半年随访,GD痊愈率76.5%、好转率19.8%、总有效率96.3%,甲亢性心脏病的治疗总有效率93.8%。其中,甲状腺功能减退症(简称甲减)者569例,占10.1%。结论131I联合碳酸锂治疗GD及合并甲亢性心脏病的GD经济、安全、方便、疗效可靠,同时可以减少131I的使用剂量。
Objective To investigate the clinical curative effects of 131I combined with lithium carbonate therapy for Graves disease (GD).Methods The clinical treatment materials of 5638 patients with GD patients were analyzed retrospectively.Results The cure rate of patients with GD after one single cycle of 131I therapy combined with lithium carbonate was 76.5%,and the improve rate was 19.8%.The total effective rate was 96.3% among the 5638 GD patients.The total effective rate was 93.8% among 178 GD patients with hyperthyroid cardiopathy.Among all GD patients,the patients with hypothyroidism was observed 569 (10.1%) after the first 131I therapy.Conclusion 131 I combined with lithium carbonate therapy is an effective simple and safe method for the treatment of GD patients and GD patients with hyperthyroid cardiopathy.It may decrease the 131I treatment dose.
出处
《标记免疫分析与临床》
CAS
2014年第3期241-242,共2页
Labeled Immunoassays and Clinical Medicine